1. Introduction {#sec1-ijerph-16-00995}
===============

Despite numerous technical advances in the administration of in vitro fertilization (IVF) to infertile couples, embryo implantation remains the rate-limiting step for a successful IVF procedure \[[@B1-ijerph-16-00995]\]. The endometrium is receptive to the embryo only during a period known as the implantation window. During this period, both the developing embryo and the receptive endometrium undergo a synchronized complex process involving several factors including immune cells, growth factors, cytokines and adhesion molecules \[[@B2-ijerph-16-00995],[@B3-ijerph-16-00995]\]. It is believed that the events underlying the endometrial receptivity are products of several genes; therefore, alterations due to polymorphisms in genes involved in embryo implantation could lead to IVF failure \[[@B4-ijerph-16-00995],[@B5-ijerph-16-00995]\].

Among the large number of embryo implantation failure or miscarriage-related factors, interleukins those involved in abnormal immune reactions are particularly notable \[[@B6-ijerph-16-00995]\]. Interleukins are a group of immunomodulatory proteins that mediate several immune reactions in human body. The interleukin (IL)-1 system is composed of a family of peptides, including two agonists, IL-1α and IL-1β. IL-1α may have a critical function in the development of obesity \[[@B7-ijerph-16-00995]\]. Increasing body weight is associated with significantly lower progesterone concentrations in early pregnancy after blastocyst transfer and affects the IVF outcome \[[@B8-ijerph-16-00995]\]. IL-3 is a haematopoiesis promoting factor and aids in embryo implantation and placental development, whose maternal serum level increases as a function of the trimester \[[@B9-ijerph-16-00995]\]. IL-3 gene polymorphisms were associated with acute rejection after kidney transplantation \[[@B10-ijerph-16-00995]\]. IL-6 plays a role in reproduction and immune balance, acting as a multifunctional cytokine with anti- and pro-inflammatory response and regulates the behaviour of the gestational tissues \[[@B11-ijerph-16-00995]\]. Liu et al. demonstrated a possible association between IL-6-174 promoter polymorphism and recurrent spontaneous abortion \[[@B12-ijerph-16-00995]\]. IL-15 is implicated in the recruitment and proliferation of uterine natural killer (NK) cells in the endometrium \[[@B13-ijerph-16-00995]\]. Increased expression of IL-15 in the placenta tissue of patients may be connected to disturbed implantation with following foetal loss \[[@B14-ijerph-16-00995]\]. IL-18, mainly produced by macrophages, stimulates IFN-γ production and activates NK and T cells, which are involved in uterine implantation \[[@B15-ijerph-16-00995]\]. Serum IL-18 level is associated with response to ovarian stimulation and plays an important role in a successful pregnancy outcome after IVF treatment \[[@B16-ijerph-16-00995]\].

Studies have illustrated that genetic variations in IL genes responsible for regulating the activity of the immune system might cause embryo implantation failure or early pregnancy loss \[[@B17-ijerph-16-00995]\]. After meta-analysis, a systematic review indicated that a significant association between IL-1β (-511C/T) polymorphism and recurrent miscarriage (RM) \[[@B18-ijerph-16-00995]\]. Likewise, research conducted in Iranian women has revealed a relationship between the *IL-6* rs1800796 (−634C/G) polymorphism and an increased risk of RM \[[@B19-ijerph-16-00995]\]. In addition, Yue et al. showed that the IL-18-137G/C gene polymorphism may contribute to pathogenesis of idiopathic RM in Chinese Han population. Al-Khateeb et al. reported that two SNPs of IL-18 (rs360717 and rs1946519) are significantly associated with RM \[[@B15-ijerph-16-00995]\]. Finally, the effects of IL-3 and IL-15 polymorphisms on pregnancy outcomes have not been studied yet. It must be highlighted that none of the above studies were conducted in an IVF population. Therefore, we decided to assess the possible correlations between the IL polymorphisms and pregnancy outcomes based on IVF population. Our findings would be of value as a prognostic indicator of successful IVF outcomes.

2. Materials and Methods {#sec2-ijerph-16-00995}
========================

2.1. Study Design and Subjects {#sec2dot1-ijerph-16-00995}
------------------------------

Women undergoing IVF at the Lee Women's Hospital in Taichung, Taiwan (n = 1015) were prospectively enrolled in the study from January 2014 to December 2015. The causes of infertility included male factor, tubal factor, endometriosis, polycystic ovarian syndrome (PCOS), advance maternal age, unexplained and others. Eligibility inclusion criteria were: (1) a woman age ≤ 40 years old; (2) undergoing the first IVF or intracytoplasmic sperm injection (ICSI) cycle; and (3) blastocyst transfer in the fresh cycle. Exclusion criteria were autoimmune dysfunction, genetic anomalies, inflammatory disease and other systemic disorders. A venous blood sample was drawn for DNA extraction with subsequent interleukin genotyping. Ethics approval (CS13194) was obtained from the Institutional Review Board of Chung Shan Medical University Hospital.

We studied the effects of the following six single-nucleotide polymorphisms (SNPs) in five IL genes on IVF outcomes: IL-1α C/T rs1800587 (C\_\_\_9546481_20), IL-3 C/T rs40401 (C\_\_\_2397269_30), IL-6 C/G rs1800795 (C\_\_\_1839697_20), IL-15 A/T rs3806798 (C\_\_27519194_10), IL-18 C/G rs187238 (C\_\_\_2408543_10) and IL-18 G/T rs1946518 (C\_\_\_2898460_10). The details of the selected SNP were described in [supplementary Table S1](#app1-ijerph-16-00995){ref-type="app"}. Relevant IVF outcomes were clinical pregnancy, embryo implantation, abortion and live birth. Clinical pregnancy was defined as the presence of an intrauterine gestational sac (GS). Embryo implantation rate was calculated by dividing the number of implanted GS by the number of embryos transferred. Spontaneous abortion is defined as the natural loss of a pregnancy with an ultrasound-confirmed GS before 20 gestational weeks. Live birth was considered birth after 24 weeks of gestation.

2.2. IVF Treatment Protocol {#sec2dot2-ijerph-16-00995}
---------------------------

The details of a stimulation cycle procedure have been previously described \[[@B20-ijerph-16-00995]\]. Patients underwent either a standard long protocol using the gonadotrophin-releasing hormone (GnRH) agonist or a short protocol using GnRH antagonists. The long protocol began with daily subcutaneous injections of 0.5 mg of leuprolide acetate (Lupron; Takeda Pharmaceutics, Konstantz, Germany) from cycle Day 21 of the previous cycle. On cycle day 3, recombinant FSH (Gonal-F, Merck-Serono, Darmstadt, Germany) or highly purified FSH (Menopur; Ferring Pharmaceuticals, Kiel, Germany) was administered via individual set with flexible doses. Patients on the antagonist protocol had gonadotrophin stimulation initiated on day 3 of the cycle and the GnRH antagonist (Orgalutran; Organon Laboratories) at a daily dose of 0.25 mg was administered using a fixed day 6 protocol. Final oocyte maturation was triggered with 10,000 IU human Chorionic Gonadotropin (Profasi; Serono) and oocyte retrieval was performed 36 to 38 hours later. Fertilization was carried out either by conventional insemination or ICSI depending on the semen parameters. Fresh blastocyst transfer was performed throughout the study period.

2.3. DNA Extraction and Determination of Genotypes {#sec2dot3-ijerph-16-00995}
--------------------------------------------------

Genomic DNA was extracted from EDTA anti-coagulated venous blood using a QIAamp DNA blood mini kit (Qiagen, Valencia, USA), according to the manufacturer's instructions described in detail previously \[[@B21-ijerph-16-00995]\]. DNA was dissolved in TE buffer (10 mM Tris and 1 mM EDTA acid; pH 7.8) and then quantitated by a measurement of the optical density at 260 nm. The final preparation was stored at −20 °C and used as templates for polymerase chain reaction (PCR). Allelic discrimination of the six studied SNPs was assessed with the ABI StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and analysed using SDS vers. 3.0 software (Applied Biosystems, Foster City, CA, USA), with the TaqMan assay \[[@B22-ijerph-16-00995]\].

2.4. Statistical Analysis {#sec2dot4-ijerph-16-00995}
-------------------------

The demographic data and other clinically relevant data of continuous variables are presented as mean and standard deviation, whereas categorical variables were presented as percentage. The chi-square test was used to investigate the different effects of IL polymorphisms on IVF outcome. Continuous variables between the 2 groups were compared using the Student's t-test. All data were analysed using the IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY). *p*-values \< 0.05 were considered statistically significant.

3. Results {#sec3-ijerph-16-00995}
==========

There were 1015 patients attempting their first fresh cycle of IVF. The genotypic frequencies of IL SNPs are shown in [Table 1](#ijerph-16-00995-t001){ref-type="table"}. Genotypic distributions of IL-1α (rs1800587 C/T), IL-3 (rs40401 C/T), IL-18 (rs187238 C/G) and IL-18 (rs1946518 G/T) conformed to Hardy-Weinberg equilibrium (*p* = 0.469, χ2 value: 0.525; *p* = 0.486, χ2 value: 0.528; *p* = 0.330, χ2 value: 0.950 and *p* = 0.873, χ2 value: 0.025; respectively), except for IL-15 (rs3806798 A/T) (*p* = 0.030, χ2 value: 4.723). The following notation will be used for describing the genotypes of all SNPs: homozygous major as "AA," heterozygous as "Aa" and homozygous minor as "aa." The genotypes frequencies of IL-6 polymorphism were AA (100%), Aa (0%) and aa (0%). [Table 2](#ijerph-16-00995-t002){ref-type="table"} outlines the baseline and IVF treatment cycle characteristics of 1015 IVF patients.

[Table 3](#ijerph-16-00995-t003){ref-type="table"} shows the association between IL polymorphisms and IVF outcomes. There were no statistically significant differences found in clinical pregnancy, embryo implantation, abortion or live birth rates. We did not examine the association between IL-6 polymorphism and IVF outcomes because of the 100% frequency of the homozygous major genotype. Combining the genotypes with the minor allele (Aa/aa) and comparing them to the homozygous major genotype (AA) yielded statistically insignificant results for clinical pregnancy, embryo implantation or live birth rates. However, a statistically significant difference in abortion rate was found for the recessive model of IL-3 SNP (16.5% for AA and 7.9% for Aa/aa, *p* = 0.025) ([Table 4](#ijerph-16-00995-t004){ref-type="table"}).

The baseline and IVF treatment cycle characteristics of IL-3 polymorphism patients were shown in [Table 5](#ijerph-16-00995-t005){ref-type="table"}. The baseline characteristics of the both subgroups (AA and Aa/aa), especially age, ovarian reserve indexes and infertility duration, were not statistically different. Also, no significant differences were observed in the factors thought to affect the outcome measures during IVF treatment, including the number of mature oocytes, fertilization rates, Day 5 good embryo rate, number of transferred embryos and endometrial thickness.

4. Discussion {#sec4-ijerph-16-00995}
=============

Throughout its 40-year history, IVF has improved significantly. However, implantation and pregnancy rates with IVF have increased slowly year after year \[[@B23-ijerph-16-00995]\]. Therefore, a more specific recognition of patients' individual genetic profiles may be helpful in the appraisal of each woman's intrinsic capacity to become pregnant. In this study, the maternal genetic profile at six gene polymorphisms associated with immune and inflammation were investigated in a cohort of IVF patients and IL-3 was shown to be associated with IVF abortion. To the best of our knowledge, our study is the first to report that the IL-3 genetic polymorphism can affect abortion rates in Taiwan Han IVF population.

It must be emphasized that only one study was done to investigate the relationships between the IL polymorphisms and IVF outcomes and found that IL-1 receptor antagonist gene polymorphism is associated with a poor prognosis of obtaining a pregnancy after IVF \[[@B24-ijerph-16-00995]\]. In our study, we found no association between IL-1α, IL-15 or IL-18 SNPs and IVF outcomes. However, a meta-analysis showed that the IL-18 polymorphism is associated with an increased risk of recurrent pregnancy loss \[[@B18-ijerph-16-00995]\]. A possible explanation for this discrepancy is that our study was conducted in an IVF population, whereas the populations pooled for the meta-analysis were not IVF subjects.

This study revealed that *IL-3* rs40401 C/T polymorphisms had higher abortion rate in IVF patients. Spontaneous miscarriage is the most common complication of pregnancy and occurs in 10--15% of pregnancies during the first trimester \[[@B25-ijerph-16-00995]\]. The mechanisms of pregnancy loss are not completely understood. It is believed that apart from chromosomal, embryonic and anatomical defects, immunologic rejection of the embryo by the maternal immune system may be involved \[[@B26-ijerph-16-00995]\].

To maintain a healthy pregnancy, human endometrial endothelial cells (HEECs) produce a number of chemokines and proangiogenic factors that may promote immune cell recruitment, trophoblast invasion and spiral artery remodelling, which establishes the adequate placentation and vascular development \[[@B27-ijerph-16-00995]\]. Women with antiphospholipid antibodies (aPL) are at risk for pregnancy loss \[[@B28-ijerph-16-00995]\]. Previous in vitro studies have revealed that aPL inhibits HEEC vascular endothelial growth factor secretion and their ability to form vessel-like structures \[[@B29-ijerph-16-00995],[@B30-ijerph-16-00995]\]. A systemic review also showed that aPL can directly affect trophoblast function and lead to impaired placentation and vascular transformation \[[@B31-ijerph-16-00995]\].

Women with pregnancy loss due to the anti-phospholipid antibody syndrome (APS) have reduced levels of IL-3 \[[@B32-ijerph-16-00995]\]. IL-3 belongs to the family of hematopoietic cytokines \[[@B33-ijerph-16-00995]\] and is a growth factor for the trophoblast that assists in embryo implantation and placental development \[[@B34-ijerph-16-00995]\]. Mice with aPL-induced foetal loss have low levels of IL-3 and administration of recombinant IL-3 to the affected mice increased pregnancy success \[[@B35-ijerph-16-00995]\]. The mechanism by which IL-3 reverses the effects of aPL on pregnancy is not completely understood. Di Simone et al. \[[@B36-ijerph-16-00995]\] submitted that IL-3 can reverse the effects of aPL on hormone secretion and trophoblast invasion. However, Chamley et al. question if it has the same effects on human trophoblasts \[[@B37-ijerph-16-00995]\]. Savion et al. showed the ability of ciprofloxacin to reduce pregnancy loss in the mouse model, possibly through elevation of IL-3 \[[@B38-ijerph-16-00995]\].

Furthermore, IL-3 is the main cytokine for the generation of dendritic cells (DCs), which play a role in inducing T helper 2 (Th2) cell responses \[[@B39-ijerph-16-00995]\]. IL-3-treated monocyte-derived DC shifts Th cell responses toward a Th2 cytokine pattern \[[@B39-ijerph-16-00995]\]. Thus, the activity of IL-3 may influence the balance between Th1 and Th2 cytokines. Imbalance in Th1/Th2 cytokine level is a critical factor associated with foetus abortion. Th1 type response has been related to pregnancy failure, whereas the Th2 type dominant response has been associated with normal pregnancy \[[@B40-ijerph-16-00995]\]. Significantly elevated level of Th1/Th2 cytokine is present in infertile women with multiple implantation failures after IVF and in women with recurrent pregnancy losses \[[@B41-ijerph-16-00995]\].

Maternal age has great impact on IVF pregnancy outcome. The association of IL SNPs with pregnancy outcome was further analysed by stratification with age of 35 in [Table 3](#ijerph-16-00995-t003){ref-type="table"} and [Table 4](#ijerph-16-00995-t004){ref-type="table"}. We found that the impact of IL-3 SNP on abortion is borderline significantly for young age patients, which suggest that the effect of IL-3 SNP on abortion is not associated with advanced maternal age.

This study has multiple strengths. First, it used a large prospective sample size, which decreases the risk for selection bias. Second, this study included all patients undergoing their first fresh IVF cycle and consented to DNA use. Including patients who failed multiple cycles will obscure any effects of the SNPs because other factors, such as poor oocyte quality, are more likely to significantly influence the IVF outcomes. Third, we collected live birth data, which is ultimately the outcome of interest to the patient.

5. Conclusions {#sec5-ijerph-16-00995}
==============

In summary, our results indicated that IL-3 variant is associated with increased risk of abortion of IVF patients. The limitation of the study was performed only in an IVF population of Taiwan Han ethnicity. Future more large-scale population studies with inclusion of other ethnic backgrounds must be conducted to confirm that IL-3 variant rs40401 is associated with IVF abortion. The mechanism underlying the role of IL-3 in abortion remains to be determined. To define the role of IL-3, comprehensive functional experiments are also needed.
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ijerph-16-00995-t001_Table 1

###### 

The frequencies of IL-1α, IL-3, IL-6, IL-15 and IL-18 polymorphisms in in vitro fertilization (IVF) women.

  Variable    AA     Aa      aa    A Allele   a Allele                               
  ----------- ------ ------- ----- ---------- ---------- ------ ------ ------ ------ ------
  IL-1α C/T   884    87.1    128   12.6       3          0.3    1896   93.3   134    6.6
  IL-3 C/T    253    24.9    519   51.1       243        23.9   1025   50.4   1005   49.5
  IL-6 C/G    1015   100.0   0     0.0        0          0.0    2030   100    0      0
  IL-15 A/T   739    72.8    264   26.0       12         1.2    1742   85.8   288    14.1
  IL-18 C/G   748    73.7    251   24.7       16         1.6    1747   86     283    13.9
  IL-18 G/T   257    25.3    510   50.2       248        24.4   1024   50.4   1006   49.5

AA: homozygous major, Aa: heterozygous, aa: homozygous minor.

ijerph-16-00995-t002_Table 2

###### 

Clinical characteristics of women undergoing IVF treatment.

  Number of Patients                      1015
  --------------------------------------- -------------
  Mean patient age (years)                35.5 ± 4.6
  Cause of infertility                    
  Male factor (%)                         208 (20.5%)
  Tubal factor (%)                        196 (19.3%)
  Endometriosis (%)                       73 (7.2%)
  PCOS (%)                                97 (9.6%)
  Unexplained (%)                         79 (7.8%)
  Advance maternal age (%)                273 (26.9%)
  Multiple factors (%)                    89 (8.7%)
  Total gonadotropins administered (IU)   2921 ± 892
  Basal FSH (mIU/mL)                      7.1 ± 4.4
  Basal LH (mIU/mL)                       6.5 ± 0.3
  Basal AMH (mIU/mL)                      3.1 ± 0.1
  Basal estradiol (pg/mL)                 52.3 ± 2.5
  Peak estradiol (pg/mL) \*               1892 ± 1342
  No. of oocytes retrieved                10 ± 6.6
  No. of blastocyst stage embryos         4.8 ±2.4
  No. of embryos transferred              2.5 ± 0.9
  Fertilization rate (%)                  82.6 ± 21.1
  Endometrial thickness (mm) \*\*         11.8 ± 2.1

Values presented as mean ± standard deviation. \* levels on the trigger day, \*\* thickness on the day of embryo transfer.

ijerph-16-00995-t003_Table 3

###### 

Effect of Interleukin polymorphisms on IVF outcome.

  Variable                      Age≤35     Age\>35   Overall                                                                                
  ------------------------ ---- ---------- --------- --------- ------- ---------- -------- -------- ------- ---------- ---------- --------- -------
  **Clinical pregnancy**                                                                                                                    
   IL-1α                   N    180/444    28/64     2/2       0.242   100/440    15/64    0/1      0.903   280/884    43/128     2/3       0.358
                           \%   40.5       43.8      100.0             22.7       23.4     0.0              31.7       33.6       66.7      
                           OR   1.000      1.141     \-                1.000      1.041    0.000            1.000      1.091      4.314     
   IL-3                    N    55/117     94/250    61/143    0.213   30/136     61/269   24/100   0.939   85/253     155/519    85/243    0.305
                           \%   47.0       37.6      42.7              22.1       22.7     24.0             33.6       29.9       35.0      
                           OR   1.000      0.679     0.839             1.000      1.036    1.116            1.000      0.842      1.063     
   IL-15                   N    154/378    56/130    0/2       0.550   78/361     35/134   2/10     0.555   232/739    91/264     2/12      0.340
                           \%   40.7       43.1      0.0               21.6       26.1     20.0             31.4       34.5       16.7      
                           OR   1.000      1.101     0.000             1.000      1.283    0.907            1.000      1.150      0.437     
   IL-18 C/G               N    156/372    51/130    3/8       0.871   83/376     29/121   3/8      0.552   239/748    80/251     6/16      0.894
                           \%   41.9       39.2      37.5              22.1       24.0     37.5             32.0       31.9       37.5      
                           OR   1.000      0.894     0.831             1.000      1.113    2.118            1.000      0.996      1.278     
   IL-18 G/T               N    54/124     100/258   56/128    0.533   32/133     54/252   29/120   0.772   86/257     154/510    85/248    0.448
                           \%   43.5       38.8      43.8              24.1       21.4     24.2             33.5       30.2       34.3      
                           OR   1.000      0.820     1.008             1.000      0.861    1.006            1.000      0.860      1.037     
  **Implantation**                                                                                                                          
   IL-1α                   N    254/1070   40/151    3/5       0.122   133/1142   18/161   0/2      1.000   387/2212   58/312     3/7       0.195
                           \%   23.7       26.5      60.0              11.6       11.2     0.0              17.5       18.6       42.9      
                           OR   1.000      1.158     4.819             1.000      0.955    0.000            1.000      1.077      3.537     
   IL-3                    N    78/285     131/600   88/341    0.145   42/360     81/702   28/243   0.998   120/645    212/1302   116/584   0.133
                           \%   27.4       21.8      25.8              11.7       11.5     11.5             18.6       16.3       19.9      
                           OR   1.000      0.741     0.923             1.000      0.988    0.986            1.000      0.851      1.084     
   IL-15                   N    216/900    81/321    0/5       0.406   107/930    41/346   3/29     0.964   323/1830   122/667    3/34      0.368
                           \%   24.0       25.2      0.0               11.5       11.8     10.3             17.7       18.3       8.8       
                           OR   1.000      1.069     0.000             1.000      1.034    0.887            1.000      1.044      0.452     
   IL-18 C/G               N    219/896    75/311    3/19      0.683   108/982    39/302   4/21     0.369   327/1878   114/613    7/40      0.800
                           \%   24.4       24.1      15.8              11.0       12.9     19.0             17.4       18.6       17.5      
                           OR   1.000      0.982     0.580             1.000      1.200    1.904            1.000      1.084      1.006     
   IL-18 G/T               N    69/296     147/615   81/315    0.759   39/345     75/640   37/320   0.981   108/641    222/1255   118/635   0.719
                           \%   23.3       23.9      25.7              11.3       11.7     11.6             16.8       17.7       18.6      
                           OR   1.000      1.033     1.139             1.000      1.042    1.026            1.000      1.061      1.126     
  **Abortion**                                                                                                                              
   IL-1α                   N    13/180     1/28      0/2       0.737   16/100     3/15              0.712   29/280     4/43       0/2       1.000
                           \%   7.2        3.6       0.0               16.0       20.0                      10.4       9.3        0.0       
                           OR   1.000      0.476     0.000             1.000      1.313                     1.000      0.888      0.000     
   IL-3                    N    7/55       5/94      2/61      0.121   7/30       6/61     6/24     0.110   14/85      11/155     8/85      0.069
                           \%   12.7       5.3       3.3               23.3       9.8      25.0             16.5       7.1        9.4       
                           OR   1.000      0.385     0.232             1.000      0.358    1.095            1.000      0.387      0.527     
   IL-15                   N    8/154      6/56                0.208   13/78      6/35     0/2      1.000   21/232     12/91      0/2       0.441
                           \%   5.2        10.7                        16.7       17.1     0.0              9.1        13.2       0.0       
                           OR   1.000      2.190                       1.000      1.034    0.000            1.000      1.526      0.000     
   IL-18 C/G               N    12/156     2/51      0/3       0.614   14/83      5/29     0/3      1.000   26/239     7/80       0/6       0.610
                           \%   7.7        3.9       0.0               16.9       17.2     0.0              10.9       8.8        0.0       
                           OR   1.000      0.490     0.000             1.000      1.027    0.000            1.000      0.786      0.000     
   IL-18 G/T               N    5/54       6/100     3/56      0.721   5/32       9/54     5/29     0.985   10/86      15/154     8/85      0.867
                           \%   9.3        6.0       5.4               15.6       16.7     17.2             11.6       9.7        9.4       
                           OR   1.000      0.626     0.555             1.000      1.080    1.125            1.000      0.820      0.790     
  **Live birth**                                                                                                                            
   IL-1α                   N    159/444    27/64     2/2       0.098   73/440     9/64     0/1      0.764   232/884    36/128     2/3       0.234
                           \%   35.8       42.2      100.0             16.6       14.1     0.0              26.2       28.1       66.7      
                           OR   1.000      1.308     \-                1.000      0.823    0.000            1.000      1.100      5.621     
   IL-3                    N    45/117     85/250    58/143    0.397   19/136     46/269   17/100   0.703   64/253     131/519    75/243    0.226
                           \%   38.5       34.0      40.6              14.0       17.1     17.0             25.3       25.2       30.9      
                           OR   1.000      0.824     1.092             1.000      1.270    1.261            1.000      0.997      1.318     
   IL-15                   N    138/378    50/130    0/2       0.650   58/361     22/134   2/10     0.944   196/739    72/264     2/12      0.715
                           \%   36.5       38.5      0.0               16.1       16.4     20.0             26.5       27.3       16.7      
                           OR   1.000      1.087     0.000             1.000      1.026    1.306            1.000      1.039      0.554     
   IL-18 C/G               N    140/372    45/130    3/8       0.828   60/376     20/121   2/8      0.786   200/748    65/251     5/16      0.883
                           \%   37.6       34.6      37.5              16.0       16.5     25.0             26.7       25.9       31.3      
                           OR   1.000      0.877     0.994             1.000      1.043    1.756            1.000      0.958      1.245     
   IL-18 G/T               N    46/124     92/258    50/128    0.807   19/133     40/252   23/120   0.562   65/257     132/510    73/248    0.501
                           \%   37.1       35.7      39.1              14.3       15.9     19.2             25.3       25.9       29.4      
                           OR   1.000      0.940     1.087             1.000      1.132    1.423            1.000      1.032      1.232     

AA: homozygous major, Aa: heterozygous, aa: homozygous minor, OR: Odds ratio. *p*-Value by Chi-square test or Fisher's exact test when appropriated.

ijerph-16-00995-t004_Table 4

###### 

Effect of Interleukin polymorphisms on IVF outcome (recessive model).

  Variable                      Age≤35     Age\>35   Overall                                                      
  ------------------------ ---- ---------- --------- --------- ---------- --------- ------- ---------- ---------- -------
  **Clinical pregnancy**                                                                                          
   IL-1α                   N    180/444    30/66     0.449     100/440    15/65     0.950   280/884    45/131     0.540
                           \%   40.5       45.5                22.7       23.1              31.7       34.4       
                           OR   1.000      1.222               1.000      1.020             1.000      1.129      
   IL-3                    N    55/117     155/393   0.144     30/136     85/369    0.816   85/253     240/762    0.535
                           \%   47.0       39.4                22.1       23.0              33.6       31.5       
                           OR   1.000      0.734               1.000      1.058             1.000      0.909      
   IL-15                   N    154/378    56/132    0.735     78/361     37/144    0.323   232/739    93/276     0.484
                           \%   40.7       42.4                21.6       25.7              31.4       33.7       
                           OR   1.000      1.072               1.000      1.255             1.000      1.111      
   IL-18 C/G               N    156/372    54/138    0.567     83/376     32/129    0.523   239/748    86/267     0.938
                           \%   41.9       39.1                22.1       24.8              32.0       32.2       
                           OR   1.000      0.890               1.000      1.165             1.000      1.012      
   IL-18 G/T               N    54/124     156/386   0.537     32/133     83/372    0.680   86/257     239/758    0.566
                           \%   43.5       40.4                24.1       22.3              33.5       31.5       
                           OR   1.000      0.879               1.000      0.906             1.000      0.916      
  **Implantation**                                                                                                
   IL-1α                   N    254/1070   43/156    0.297     133/1142   18/163    0.822   387/2212   61/319     0.477
                           \%   23.7       27.6                11.6       11.0              17.5       19.1       
                           OR   1.000      1.222               1.000      0.942             1.000      1.115      
   IL-3                    N    78/285     219/941   0.157     42/360     109/945   0.947   120/645    328/1886   0.486
                           \%   27.4       23.3                11.7       11.5              18.6       17.4       
                           OR   1.000      0.805               1.000      0.987             1.000      0.921      
   IL-15                   N    216/900    81/326    0.760     107/930    44/375    0.907   323/1830   125/701    0.915
                           \%   24.0       24.8                11.5       11.7              17.7       17.8       
                           OR   1.000      1.047               1.000      1.022             1.000      1.013      
   IL-18 C/G               N    219/896    78/330    0.770     108/982    43/323    0.259   327/1878   121/653    0.519
                           \%   24.4       23.6                11.0       13.3              17.4       18.5       
                           OR   1.000      0.957               1.000      1.243             1.000      1.079      
   IL-18 G/T               N    69/296     228/930   0.673     39/345     112/960   0.857   108/641    340/1890   0.513
                           \%   23.3       24.5                11.3       11.7              16.8       18.0       
                           OR   1.000      1.068               1.000      1.036             1.000      1.083      
  **Abortion**                                                                                                    
   IL-1α                   N    13/180     1/30      0.698     16/100     3/15      0.712   29/280     4/45       1.000
                           \%   7.2%       3.3%                16.0%      20.0%             10.4%      8.9%       
                           OR   1.000      0.443               1.000      1.313             1.000      0.844      
   IL-3                    N    7/55       7/155     0.055     7/30       12/85     0.261   14/85      19/240     0.025
                           \%   12.7       4.5                 23.3       14.1              16.5       7.9        
                           OR   1.000      0.324               1.000      0.540             1.000      0.436      
   IL-15                   N    8/154      6/56      0.208     13/78      6/37      0.952   21/232     12/93      0.299
                           \%   5.2        10.7                16.7       16.2              9.1        12.9       
                           OR   1.000      2.190               1.000      0.968             1.000      1.489      
   IL-18 C/G               N    12/156     2/54      0.527     14/83      5/32      0.872   26/239     7/86       0.471
                           \%   7.7        3.7                 16.9       15.6              10.9       8.1        
                           OR   1.000      0.462               1.000      0.913             1.000      0.726      
   IL-18 G/T               N    5/54       9/156     0.358     5/32       14/83     0.872   10/86      23/239     0.598
                           \%   9.3        5.8                 15.6       16.9              11.6       9.6        
                           OR   1.000      0.600               1.000      1.096             1.000      0.809      
  **Live birth**                                                                                                  
   IL-1α                   N    159/444    29/66     0.202     73/440     9/65      0.575   232/884    38/131     0.504
                           \%   35.8       43.9                16.6       13.8              26.2       29.0       
                           OR   1.000      1.405               1.000      0.808             1.000      1.148      
   IL-3                    N    45/117     143/393   0.683     19/136     63/369    0.402   64/253     206/762    0.588
                           \%   38.5       36.4                14.0       17.1              25.3       27.0       
                           OR   1.000      0.915               1.000      1.268             1.000      1.094      
   IL-15                   N    138/378    50/132    0.779     58/361     24/144    0.869   196/739    74/276     0.926
                           \%   36.5       37.9                16.1       16.7              26.5       26.8       
                           OR   1.000      1.060               1.000      1.045             1.000      1.015      
   IL-18 C/G               N    140/372    48/138    0.553     60/376     22/129    0.771   200/748    70/267     0.869
                           \%   37.6       34.8                16.0       17.1              26.7       26.2       
                           OR   1.000      0.884               1.000      1.083             1.000      0.974      
   IL-18 G/T               N    46/124     142/386   0.950     19/133     63/372    0.477   65/257     205/758    0.583
                           \%   37.1       36.8                14.3       16.9              25.3       27.0       
                           OR   1.000      0.987               1.000      1.223             1.000      1.095      

AA: homozygous major, Aa: heterozygous, aa: homozygous minor, OR: Odds ratio. *p*-Value by Chi-square test or Fisher's exact test when appropriated.
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Baseline characteristics and IVF treatment cycle parameters of IL-3 polymorphisms patients.

  Variable                          IL-3                                    
  --------------------------------- ------------------- ------------------- -------
  Age (years)                       35.81 ± 4.82        35.46 ± 4.48        0.308
  Duration of infertility (years)   3.54 ± 2.84         3.72 ± 3.20         0.415
  Total gonadotropin doses (IU)     2350.32 ± 1512.96   2283.76 ± 1405.19   0.622
  Basal FSH (mIU/mL)                7.28 ± 5.04         6.94 ± 3.86         0.266
  Basal LH (mIU/mL)                 5.63 ± 4.59         5.75 ± 5.78         0.760
  Basal AMH (mIU/mL)                3.11 ± 2.89         3.15 ± 2.92         0.834
  Basal oestradiol (pg/mL)          36.48 ± 24.43       37.15 ± 25.14       0.711
  Peak estradiol (pg/mL) \*         1835.5 ± 1310.89    1910.04 ± 1351.89   0.509
  P4 ng/ml at HCG injection day     2.01 ± 12.73        1.55 ± 6.79         0.526
  No. of oocytes retrieved          9.52 ± 6.31         10.20 ± 6.73        0.162
  Mature oocytes                    7.54 ± 5.56         8.33 ± 6.36         0.080
  Fertilization rate (%)            81.59 ± 22.41       82.99 ± 20.58       0.481
  Day3 embryo no.                   7.82 ± 5.41         7.57 ± 5.16         0.641
  Day3 good embryo rate (%)         59.56 ± 22.67       61.63 ± 23.38       0.393
  Day5 good embryo rate (%)         45.93 ± 21.24       47.11 ± 22.78       0.734
  No. of transferred embryos        2.55 ± 0.90         2.48 ± 0.85         0.256
  Endometrial thickness (mm) \*\*   11.83 ± 1.86        11.78 ± 2.24        0.819
  Clinical pregnancy (%)            85/253 (33.6%)      240/762 (31.5%)     0.535
  Implantation (%)                  120/645 (18.6%)     328/1886 (17.4%)    0.486
  Abortion (%)                      14/85 (16.5%)       19/240 (7.9%)       0.025
  Abortion per cycle (%)            14/253 (5.5%)       19/762 (2.5%)       0.018
  Live birth (%)                    64/253 (25.3%)      206/762 (27.0%)     0.588
  Aetiology of infertility                                                  
  Male factor (%)                   53 (21.0)           174 (22.8)          0.286
  Tubal factor (%)                  44 (17.4)           137 (18.0)          0.507
  Endometriosis (%)                 15 (5.9)            47 (6.2)            1.000
  PCOS (%)                          25 (9.9)            81 (10.6)           0.745
  Unexplained (%)                   14 (5.5)            67 (8.8)            0.313
  Advance maternal age (%)          78 (30.8)           197 (25.9)          0.744
  Multiple factors (%)              24 (9.5)            59 (7.7)            1.000

CC: homozygous major, CT: heterozygous, TT: homozygous minor. Values presented as mean ± standard deviation; *p*-Value by Student's t-test. \* levels on the trigger day, \*\* thickness on the day of embryo transfer.

[^1]: These two authors contributed equally to this work.
